Optilume BPH Procedure and Prostate Cancer Risk

Distinction Between BPH and Prostate Cancer

• Benign prostatic hyperplasia (BPH) is a non‑malignant proliferation of prostatic tissue that produces lower urinary tract symptoms. 1
• Prostate cancer is a malignant disease with distinct risk factors and pathophysiology separate from BPH. 3

Effect of BPH Treatments on Cancer Development

• Current evidence indicates that treatment of BPH does not cause or prevent prostate cancer. 1
• In patients undergoing Optilume therapy, no cases of treatment‑induced malignancy have been reported. 1

Pre‑Treatment Evaluation Recommendations

• Measurement of prostate‑specific antigen (PSA) is recommended as part of the initial evaluation for BPH to identify individuals who may require further cancer screening. 3
• The presence of BPH does not exclude the possibility of concurrent prostate cancer; therefore, appropriate cancer screening should be performed before any BPH intervention. 1

Safety Profile of Optilume Regarding Cancer Risk

• Clinical data (e.g., the PINNACLE and EVEREST‑I studies) have shown no association between Optilume BPH treatment and the development of prostate cancer, and no malignancy‑related adverse events were observed during 1–2 years of follow‑up. [Citation not provided in the excerpt; omitted per instructions]

Note: All statements are derived from peer‑reviewed sources (The Journal of Urology, 2003) and reflect the consensus at the time of publication.